Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.43 - $0.65 $489 - $740
1,139 Added 2.99%
39,190 $19,000
Q1 2023

May 15, 2023

BUY
$0.46 - $0.81 $11,608 - $20,440
25,235 Added 196.9%
38,051 $23,000
Q4 2022

Feb 14, 2023

BUY
$0.5 - $261.0 $6,408 - $3.34 Million
12,816 New
12,816 $8,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.